Biotech entity
Weiss Ratings is the most frequent co-covered peer, appearing in 6 of the 9 tracked stories. Negative sentiment reaches 0% here, compared with 19% across the 251-story beat baseline for the same window. Coverage clusters in pharma, which accounts for 7 of those 9, with the remainder spread across 2 other categories.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 6 of the 9 tracked stories. Negative sentiment reaches 0% here, compared with 19% across the 251-story beat baseline for the same window. Coverage clusters in pharma, which accounts for 7 of those 9, with the remainder spread across 2 other categories. They are less corroborated than the beat average, carrying 2.1 original sources each against 3.7 for the same window. Their average consequence score of 5 runs below the beat's 6.1 for that window. That works out to roughly 1.3 stories per week across a 48-day span. The busiest single day carried 3. This profile follows 9 Biotech stories mentioning HC Wainwright across the period from July 6, 2026 to August 22, 2026.
Computed from the 9 stories linked to this entity, with beat comparisons drawn from all 251 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HC Wainwright. Shared-story counts are live from our verified record — not editorial picks.
Schikan sells 30,712 shares
Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
HC Wainwright reiterates buy rating
HC Wainwright reaffirmed its buy rating on Pharvaris shares.
UBS sets $74 price target
UBS Group issued a research note with a $74 price objective on Pharvaris.
Q1 earnings beat
Pharvaris reported Q1 EPS of -$0.70, beating the consensus estimate of -$0.82.
Weiss Ratings issues sell (d-) rating
Weiss Ratings reaffirmed a sell rating on Pharvaris shares, citing financial risks.
Wedbush raises price target to $42
Wedbush lifted its price target on Pharvaris from $41 to $42 with an outperform rating.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Source: dailypolitical.com · tickerreport.com
Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Source: dailypolitical.com · tickerreport.com
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Source: themarketsdaily.com · dailypolitical.com
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Source: The Lincolnian Online · Bbns
REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Source: Zolmax · Markets Daily
HC Wainwright is linked from 9 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
